managing patients with transplant-ineligible bdpcn with tagraxofusp
Published 1 year ago • 39 plays • Length 1:15Download video MP4
Download video MP3
Similar videos
-
1:23
the challenge of relapse in transplant-eligible & transplant-ineligible patients with bdpcn
-
1:08
tagraxofusp: a breakthrough therapy in bpdcn
-
1:09
ibrutinib added to autosct conditioning and consolidation for patients with abc-dlbcl
-
1:56
strategies for the management of ebv-ptld
-
1:48
the management of post-transplant cytopenia in patients with multiple myeloma
-
1:51
checkpoint inhibition in the treatment of mpns
-
0:49
management of patients with penta-class refractory myeloma
-
1:59
tagraxofusp-based therapy to eradicate mrd in patients with aml prior to allohct
-
6:18
synlab: leading european medical diagnostics provider
-
1:49:33
cbct treatment planning - by randolph r. resnik, dmd, mds
-
3:11
intensive chemotherapy: why the modern approach of cpx-351 is important for cure in aml
-
1:07
key advancements in the treatment of bpdcn from ebmt 2024
-
1:25
the management of cll in italy
-
3:13
targeting cd38 with a bispecific antibody to treat r/r aml: a phase i trial
-
1:21
the current role of plasmapheresis in the treatment landscape for ttp
-
1:03
using bispecific antibodies instead of chemotherapy to reach pre-transplant remission in b-all
-
1:45
mechanism of action of bitopertin to treat patients with epp
-
1:28
phase i study of pevonedistat and ibrutinib in r/r b-nhl
-
2:16
correcting the function of mutated hemoglobin with gene therapy for scd
-
1:58
clinical outcomes of patients with ebv-ptld who fail rituximab following hsct
-
5:43
pre- and post-allohsct treatment in mds